Evidence map›Paper›PMID 28319404›Full record

ArticleMolecular pharmaceutics2017

Encapsulation of an EP67-Conjugated CTL Peptide Vaccine in Nanoscale Biodegradable Particles Increases the Efficacy of Respiratory Immunization and Affects the Magnitude and Memory Subsets of Vaccine-Generated Mucosal and Systemic CD8

Bala V K Karuturi, Shailendra B Tallapaka, Pravin Yeapuri, Stephen M Curran, Sam D Sanderson, Joseph A Vetro

Open access · greenAbstract read
In one paragraph

Article in Molecular pharmaceutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Bala V K KaruturiCenter for Drug Delivery and Nanomedicine and §Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center , 986025 Nebraska Medical Center, Omaha, Nebraska 68198-6025, United States.
Shailendra B TallapakaCenter for Drug Delivery and Nanomedicine and §Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center , 986025 Nebraska Medical Center, Omaha, Nebraska 68198-6025, United States.
Pravin YeapuriCenter for Drug Delivery and Nanomedicine and §Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center , 986025 Nebraska Medical Center, Omaha, Nebraska 68198-6025, United States.
Stephen M CurranCenter for Drug Delivery and Nanomedicine and §Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center , 986025 Nebraska Medical Center, Omaha, Nebraska 68198-6025, United States.
Sam D SandersonCenter for Drug Delivery and Nanomedicine and §Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center , 986025 Nebraska Medical Center, Omaha, Nebraska 68198-6025, United States.
Joseph A VetroCenter for Drug Delivery and Nanomedicine and §Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center , 986025 Nebraska Medical Center, Omaha, Nebraska 68198-6025, United States.ORCID 0000-0003-2446-9797
Nebraska Medical Center · US

Funding

Project 9 - Renal Drug Targeting for the Treatment of Lupus NephritisP20GM103480 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BRONICH, TATIANA K · 2012 to 2017
$13.3M
TARGETED NANOCARRIER FOR SIRNA DELIVERY TO TUMOR VASCULATUREP20RR021937 · NCRR · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KABANOV, ALEXANDER V · 2008 to 2011
$8.6M
EP67-Based Targeted Mucosal Vaccines to Prevent Primary Infection with CMVR01AI121050 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI VETRO, JOSEPH ANTHONEY · 2016 to 2020
$1.9M
Response-Selective C5a Agonist for the Treatment of AsthmaR41AI094710 · NIAID · PROMMUNE, INC. · PI POOLE, JILL A · 2011 to 2012
$528k
NCRR NIH HHS P20 RR021937NIAID NIH HHS HHSN272201300006CNIAID NIH HHS R01 AI121050NIAID NIH HHS R41 AI094710NIGMS NIH HHS P20 GM103480
6 · The paper itself

Abstract

The diameter of biodegradable particles used to coencapsulate immunostimulants and subunit vaccines affects the magnitude of memory CD8

Indexed as

AnimalsCD8-Positive T-LymphocytesCytomegalovirusFemaleImmunity, MucosalMiceMice, Inbred BALB CNanoparticlesNanospheresNIH 3T3 CellsTumor Necrosis Factor-alphaVaccines, SubunitTumor Necrosis Factor-alphaVaccines, Subunitcorrelate of protectionhost-derived immunostimulantmicroparticlemicrospheremucosal adjuvantmucosal vaccinemurine cytomegalovirusnanoparticlenanospherevaccine delivery

Identifiers

PMID28319404
PMCPMC5659116
OpenAlexW2599869932

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.